TransCode Therapeutics Publishes Preclinical Data Supporting TTX-MC138 for Glioblastoma Treatment

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announced the publication of peer-reviewed preclinical research supporting the use of its lead candidate, TTX-MC138, for the treatment of glioblastoma multiforme, one of the most aggressive forms of brain cancer. The study, conducted in collaboration with Michigan State University and published in the Journal of Functional Biomaterials, demonstrated that systemic delivery of TTX-MC138 successfully reached brain tumors in orthotopic glioblastoma models, significantly increased tumor cell apoptosis, and resulted in a statistically significant improvement in survival. The findings further validate TransCode's TTX delivery platform and support the potential advancement of TTX-MC138 into future clinical evaluation for patients with glioblastoma, building on completed IND-enabling studies and existing Phase 1 clinical experience outside the central nervous system.

The importance of this research lies in addressing one of the most challenging cancers to treat, with glioblastoma having limited effective treatment options and poor prognosis. The ability of TTX-MC138 to reach brain tumors through systemic delivery represents a significant advancement, as the blood-brain barrier has historically posed a major obstacle for cancer therapeutics targeting brain cancers. The statistically significant improvement in survival observed in preclinical models suggests potential clinical benefit for patients facing this devastating diagnosis. The research builds upon TransCode's focus on treating metastatic tumors that overexpress microRNA-10b, a unique biomarker of metastasis that represents a promising therapeutic target.

This publication in a peer-reviewed journal adds scientific credibility to TransCode's platform and provides validation for investors and the scientific community. The company's progress with TTX-MC138 comes at a time when innovative approaches to treating aggressive cancers are urgently needed, particularly for cancers like glioblastoma that have seen limited therapeutic advances in recent years. The successful demonstration of tumor targeting and apoptosis induction in brain tumors supports the potential for TTX-MC138 to address unmet medical needs in neuro-oncology. Additional information about TransCode Therapeutics is available through their corporate communications at https://ibn.fm/RNAZ.

The implications of this research extend beyond glioblastoma, as the TTX delivery platform may have applications for other difficult-to-treat cancers. The ability to target specific biomarkers like microRNA-10b represents a precision medicine approach that could improve therapeutic outcomes while potentially reducing side effects. As TransCode moves toward potential clinical evaluation of TTX-MC138 for glioblastoma, this preclinical data provides a strong foundation for regulatory discussions and future trial design. The collaboration with Michigan State University highlights the importance of academic-industry partnerships in advancing innovative cancer therapies from bench to bedside.